Form 4: Arcus Biosciences President Sells Shares Under 10b5-1 Plan

Arcus Biosciences President Juan C. Jaen sold a total of 50,000 shares of common stock in multiple transactions under a Rule 10b5-1 trading plan.

Summary

• Juan C. Jaen, President of Arcus Biosciences, Inc. (RCUS), reported sales of common stock.
• Transactions occurred on November 17, 2025, and November 18, 2025.
• A total of 50,000 shares were sold across three separate transactions.
• On November 17, 2025, 37,114 shares were sold at a weighted average price of $20.2274, with prices ranging from $19.65 to $20.645.
• Also on November 17, 2025, 7,836 shares were sold at a weighted average price of $20.713, with prices ranging from $20.65 to $20.82.
• On November 18, 2025, 5,050 shares were sold at a weighted average price of $19.75, with prices ranging from $19.48 to $20.17.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Jaen on August 8, 2025.
• Following these transactions, Jaen beneficially owns 1,037,060 shares indirectly through a trust and 367,220 shares directly.

Sentiment

Score: 5

Explanation: The sales by President Juan C. Jaen were executed under a pre-established Rule 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new material non-public information. While insider selling can sometimes be viewed negatively, the pre-planned nature makes it a neutral event in this context.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new, undisclosed information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence or a signal that the insider believes the stock price may not significantly appreciate in the near term.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide specific information related to broader industry trends or competitors. It reflects an individual executive's portfolio management decisions.

Stakeholder Impact

• Shareholders may interpret insider selling, even if planned, as a minor negative signal regarding management's confidence in the near-term stock price, potentially leading to slight shifts in investor sentiment.

Key Dates

Recommendation

This Form 4 filing reports routine insider selling under a pre-established 10b5-1 plan. It does not provide new fundamental information about Arcus Biosciences' operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Investors should consider this a planned liquidity event for the insider rather than a strong signal for the company's future performance.

Keywords

Arcus Biosciences, RCUS, insider trading, Form 4, stock sale, Juan C. Jaen, 10b5-1 plan